Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study.

medRxiv : the preprint server for health sciences·2026
Same author

Utility of liquid-based cytology and cell block obtained by vitrectomy under infusion to diagnose vitreoretinal lymphoma.

Japanese journal of ophthalmology·2026
Same author

Potential and biases of large language model simulation for public surveys on Alzheimer's disease therapies.

Journal of Alzheimer's disease : JAD·2026
Same author

Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Seed Amplification Assays for Parkinson's Disease: A Review of α-Synuclein Assays in Body Fluids and Tissues.

Journal of neurochemistry·2026
Same author

Comparison of percutaneous and transarterial fiducial marker placement before proton therapy for pancreatic cancer.

Journal of radiation research·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Kenichiro Sato1, Yoshiki Niimi2, Ryoko Ihara3

  • 1The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary

Correcting plasma phosphorylated tau (p-tau) for kidney function in Alzheimer's disease (AD) diagnostics alters test performance. Adjustments are crucial, especially in chronic kidney disease (CKD) populations, to ensure accurate blood-based biomarker results.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Biomarkers for neurodegenerative diseases
  • Clinical diagnostics and performance evaluation

Background:

  • Plasma phosphorylated tau (p-tau) shows promise as a less-invasive Alzheimer's disease (AD) biomarker.
  • Elevated p-tau in chronic kidney disease (CKD) necessitates careful consideration of renal function correction.
  • Renal function correction can impact the sensitivity and specificity of p-tau assays.

Purpose of the Study:

  • To evaluate how correcting for renal function affects the performance of plasma p-tau assays.
  • To quantify the changes in sensitivity and specificity due to renal function correction.
  • To assess the impact of CKD prevalence on these performance alterations.

Main Methods:

  • Analysis of plasma p-tau217 data from a Japanese cohort study.
  • Comparison of predictive models with and without renal function correction terms.
  • Assessment of differences in sensitivity and specificity before and after correction.

Main Results:

  • Renal function correction decreased sensitivity by ~0.06 and increased specificity by ~0.09.
  • Higher CKD proportions in samples correlated with greater sensitivity decline and specificity increase.
  • Performance metric deviations, though modest, are significant in CKD-heavy cohorts.

Conclusions:

  • Renal function correction is vital for accurate blood-based biomarker (BBM) application in AD.
  • The impact of correction on sensitivity and specificity is not negligible, especially with high CKD prevalence.
  • Disclosing CKD proportion in study samples is recommended for transparent BBM performance reporting.